TELA Bio Inc risk profile
55 Elevated one input has moved against it
Measured 22 October 2026 from TELA's filed statements. Recomputed nightly.
55 (Elevated), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 69 | Stretched | Volatile | One-year price volatility — 94.0% |
| Operating pressure | 2 | Contained | Easing | Input-cost exposure — 0.03 |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.02x |
| Leverage and coverage | 82 | Acute | Worsening | Net debt to EBITDA |
| Competitive position | 60 | Stretched | Worsening | Operating-margin gap against peers — -21.5 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.